Phase 1Completed
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
A Phase 1, 6-part, Open-label, Fixed-sequence Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Single-dose Pharmacokinetics of KarXT and Effects of KarXT on the Single-dose Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company (Industry)
- Enrollment
- 133 enrolled
- Conditions
- Healthy Volunteers
- Interventions
- Xanomeline/Trospium Chloride; Lithium; Valproic Acid; Lamotrigine
- Ages
- adults, older adults
- Registry
- NCT06729970
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the effects of lithium, valproic acid, and lamotrigine on the single-dose pharmacokinetics (PK) of KarXT and the effect of KarXT on the single-dose PK of lithium, valproic acid, and lamotrigine in healthy participants.
Primary outcomes
- Maximum observed plasma concentration (Cmax)
- Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
History
Last registry update
Primary completion
Started
Registered